page banner
Press release
Dec 16, 2021
Essential Pharma significantly expands its Global Portfolio with product acquisitions for ocular and postpartum therapies from world leading pharmaceutical company

Zug, Switzerland – 16 December, 2021 – Essential Pharma, an international specialty pharma group focused on maintaining access to mature, well-established prescription pharmaceutical products essential to patients across multiple therapeutic areas, announces the acquisition from Novartis of worldwide rights (excluding US and India) to Iopidine for the adjunctive treatment of glaucoma, and Methergine for treating post-partum haemorrhage. The products are sold in over 50 countries worldwide, and their acquisition brings significant expansion to Essential Pharma’s portfolio as the company executes on its global growth ambitions.

The acquisition of these clinically well-established products from Novartis underlines Essential Pharma’s strategy of becoming a leading provider of a diverse range of essential specialty therapies across international markets. The acquisition of Iopidine and Methergine introduces two new therapeutic areas to the business – ophthalmology and emergency obstetric medicine – and will make a significant contribution to Essential Pharma’s business, providing an important opportunity for further value creation once they are successfully integrated.

These product acquisitions also confirm Essential Pharma’s position as an ideal partner for global and regional pharmaceutical companies looking to streamline their portfolios by divesting mature, well-established products that remain clinically essential for patients.

Steen Vangsgaard, CEO of Essential Pharma commented, “We are delighted to announce the acquisition of these two long-standing therapies that will play a major role in our strategy to create a highly diversified portfolio of essential medicines on an international scale. We recognise the value and potential of the acquired products and are pleased that Novartis has chosen us as a partner for their divestment. These products will complement our market presence particularly in Europe, the Middle East, Africa and Asia and allow us to further expand our sales and distribution channels in these territories.”